.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FD05_TrastuzumabDuocarmazine.TrastuzumabDuocarmazine .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FD05_TrastuzumabDuocarmazine.TrastuzumabDuocarmazine| name: | TrastuzumabDuocarmazine | |
| ATC code: | L01FD05 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 1.2 | mg |
| volume of distribution: | 3.8 | L |
| clearance: | 0.36 | L/day |
| other parameters in model implementation | ||
Trastuzumab duocarmazine is an antibody-drug conjugate consisting of trastuzumab, a HER2-targeted monoclonal antibody, linked to the cytotoxic agent duocarmazine (a DNA-alkylating agent). It is developed for the treatment of HER2-positive cancers, including metastatic breast cancer, and is approved in some regions under the trade name 'Enhertu'. Its mechanism involves delivering the cytotoxic compound selectively to HER2-expressing tumor cells.
Pharmacokinetic estimates are based on available limited data from public clinical trials and regulatory assessment reports in adults with advanced HER2-positive solid tumors, including breast cancer. No peer-reviewed publication offers full compartmental PK parameter disclosure.